POZEN INC /NC 4
4 · POZEN INC /NC · Filed Aug 31, 2015
Insider Transaction Report
Form 4
POZEN INC /NCPOZN
PLACHETKA JOHN R
DirectorPresident, CEO and Chairman10% Owner
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2015-08-27−154,486→ 154,486 totalExercise: $8.83→ Common Stock (154,486 underlying)
Footnotes (2)
- [F1]The Option shall become exercisable as follows: (a) 100% of the Option will become exercisable upon FDA Approval of YOSPRALA(TM) ("FDA Approval") by December 31, 2015; (b) 75% of the Option shall become exercisable upon FDA Approval between January 1, 2016 and March 31, 2016 with 25% of the Option automatically terminating on January 1, 2016 without ever becoming exercisable; or (c) 50% of the Option shall become exercisable upon FDA Approval between April 1, 2016 and June 30, 2016 with the remaining 25% of the Option automatically terminating on April 1, 2016 without ever becoming exercisable.
- [F2]The Option shall terminate on August 27, 2025, or, if FDA Approval is not received by June 30, 2016, the Option shall expire without ever becoming exercisable at 5:00 p.m. EDT on June 30, 2016.